Dr. Mehling is the founder and chief medical officer of Mehling Orthopedics and BHI Therapeutic Sciences (BHITS). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is also spearheading groundbreaking research in stem cell therapy. Notably, BHITS is currently engaged in an FDA Investigational New Drug trial for stroke, using human umbilical cord blood (hUCB) stem cells.
Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a Ph.D. in Chemistry (which he is currently completing at Seton Hall University). Dr. Mehling is also a member of the prestigious International Society for Stem Cell Research (ISSCR).
Dongecheng Wu, MD, Ph.D., manager and chief scientist of Wuhan Hamilton Biotechnology Co., Ltd. and his team will begin a study entitled “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis.” Dr. Wu is also the chairman of the Scientific Advisory Board of BHI Therapeutic Sciences.
Dr. Wu is a Professor at Wuhan University School of Basic Medical Science and a Chu Tian Scholar.
BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke.
For more information, please visit www.bhisciences.com.
